Jade Biosciences develops monoclonal antibody therapies for autoimmune diseases, with company updates centered on clinical execution, pipeline expansion, and financing. Its lead program, JADE101, targets APRIL and is being developed for immunoglobulin A nephropathy; additional programs include JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, and JADE301, an antibody program in preclinical development.
Recurring news includes financial results, corporate updates, clinical and biomarker data presentations, research conference participation, private placement financing, equity inducement grants, and leadership changes tied to the company's research and development organization.
Jade Biosciences (JBIO) will participate in four healthcare conferences, beginning with Guggenheim’s Healthcare Innovation Conference on November 10, 2026.
Additional fireside chats are scheduled at Stifel on November 11, UBS on November 16 and Jefferies on November 17. Management will host one-on-one investor meetings. Live webcasts will be available on Jade’s Events page, with replays accessible for 90 days after each event.
Jade Biosciences (JBIO) now expects to initiate its EVERGREEN Phase 3 trial of JADE101 in the fourth quarter of 2026. The company describes the timing as ahead of schedule for the investigational treatment for immunoglobulin A nephropathy, an autoimmune kidney disease.
Jade also expects interim data from the ongoing JUNIPER Phase 2 trial in the second quarter of 2027. Three posters at ASN Kidney Week 2026 will cover both trials and a model-based assessment integrating clinical and biomarker data to inform dose selection and anticipated treatment responses. EVERGREEN is planned as a randomized, double-blind, placebo-controlled study; JUNIPER is an open-label study.
Jade Biosciences (JBIO) announced preclinical results for JADE301, an antibody in development for dermatomyositis, at the EADV Congress in Vienna.
JADE301 selectively bound interferon beta, an immune signaling protein, with approximately 2.5-fold higher affinity than a dazukibart comparator. It was approximately 8-fold more potent at suppressing a disease-relevant signaling marker in human skin cells. In non-human primates, its half-life—the time for concentrations to fall by half—was approximately 25 days after subcutaneous dosing and approximately 30 days after intravenous dosing. Modeling predicted human subcutaneous bioavailability of approximately 73%–75%. JADE301 was well tolerated at all evaluated subcutaneous doses, with no treatment-related tissue findings.
Jade expects a Phase 1 trial in 24 healthy volunteers to begin in the fourth quarter of 2026, with interim data anticipated in the second half of 2027.
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotech focused on autoimmune diseases, will participate in several September 2026 investor and healthcare conferences, including fireside chats at Wells Fargo (Sept 8, 3:45 p.m. ET), Citi (Sept 9, 9:20 a.m. ET), H.C. Wainwright (Sept 15, 1:00 p.m. ET) and the Stifel Virtual Immunology and Inflammation Forum (Sept 23, 10:30 a.m. ET).
Jade management will also hold one-on-one investor meetings, and live webcasts of the Wells Fargo, Citi and H.C. Wainwright sessions will be available on the company’s website, with replays accessible for 90 days.
Jade Biosciences (Nasdaq: JBIO) reported second quarter 2026 results and major pipeline progress, highlighted by positive interim Phase 1 data for JADE101 in IgA nephropathy showing ~70% mean IgA reduction after a single 700 mg dose, durable biomarker effects supporting potential 12‑week subcutaneous maintenance dosing, and favorable tolerability.
The company has begun a Phase 2 JADE101 IgAN trial with interim data expected in 2027 and plans a registrational Phase 3 in 1H 2027, pending FDA feedback. Dosing began in a Phase 1 trial of JADE201 in rheumatoid arthritis, with biomarker‑rich data expected in 2027.
Jade unveiled JADE301 for dermatomyositis, aiming to start a Phase 1 healthy volunteer trial in Q4 2026 with interim data in 2H 2027. The company completed a $172.5 million public offering and ended June 30, 2026 with $461.2 million in cash, cash equivalents and investments, which it expects will fund operations into Q4 2028. Q2 2026 R&D expenses were $50.1 million, G&A expenses were $8.9 million, and net loss was $55.8 million.
Jade Biosciences (Nasdaq: JBIO), a clinical-stage biotechnology company developing antibody-based therapies for autoimmune diseases, appointed Mark Eisner, M.D., M.P.H. to its Board of Directors, effective June 25, 2026.
Dr. Eisner brings over 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen, and Genentech/Roche.
Jade Biosciences (Nasdaq: JBIO) closed a public offering of 11,500,000 common shares, including 1,500,000 from full exercise of underwriters’ option, at $15.00 per share.
The deal generated $172.5 million in gross proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) priced a public offering of 10,000,000 common shares at $15.00 per share, for expected gross proceeds of $150 million before expenses. Underwriters have a 30-day option for up to 1,500,000 extra shares.
According to Jade Biosciences, net proceeds plus existing cash will fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes. The offering is expected to close on June 5, 2026, subject to customary conditions.
Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares. All securities will be sold by Jade, with underwriters receiving a 30-day option for up to 15% additional securities. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) reported positive interim Phase 1 results for JADE101, an anti-APRIL antibody for IgA nephropathy. A single 700 mg dose produced ~70% mean IgA reduction sustained at 12 weeks with favorable tolerability and no serious adverse events.
Modeling suggests >70% IgA reductions at steady state using a 700 mg induction followed by 350 mg subcutaneous maintenance dosing every 12 weeks. Phase 2 in IgAN is underway, with interim data expected in 2027 and a Phase 3 trial planned for the first half of 2027.